Cancer drug development comes of age

Cancer impacts people of all ages.
New treatments should too.

Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. We are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. We are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.

Calling all pediatric oncologists

Join our community of pediatric oncology investigators intent on advancing treatments for childhood cancer.

Promising pipeline

Explore our clinical-stage portfolio aimed at improving cancer treatments for both children and adults.

Current trial

Clinical study evaluating DAY101 in children and young adults with relapsed or progressive low-grade glioma with an activating BRAF alteration.

Ingenious teammates wanted

Team up with bold thinkers who are passionate about making a real difference in the way we treat cancer.


In the news

August 04, 2021

Day One Biopharmaceuticals to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference

read more

July 27, 2021

Day One Receives FDA Rare Pediatric Disease Designation for DAY101 for the Treatment of Pediatric Low-Grade Glioma

read more

June 21, 2021

Day One Receives Orphan Designation from the European Commission for DAY101 for the Treatment of Glioma

read more